A Randomized Clinical Trial Evaluating Combination Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of Proliferative Diabetic Retinopathy
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Faricimab (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- 31 Jan 2025 New trial record